The widespread adoption of HoLEP as a gold-standard treatment for BPH is built upon a strong foundation of high-quality clinical evidence. This chapter reviews the key landmark clinical trials that have established the safety, efficacy, and durability of HoLEP, and have positioned it as a superior alternative to traditional surgical options.
The Gilling et al. Studies: The Foundation of HoLEP
The pioneering work of Gilling and his colleagues in New Zealand laid the groundwork for the development and validation of HoLEP. Their initial studies in the late 1990s and early 2000s were instrumental in demonstrating the feasibility and safety of the procedure. These early trials established the fundamental principles of the HoLEP technique and provided the initial evidence of its efficacy.
The Kuntz et al. Randomized Controlled Trial: HoLEP vs. TURP
One of the most influential studies in the history of HoLEP was the randomized controlled trial by Kuntz and colleagues, published in 2004. This study directly compared HoLEP to TURP in a large cohort of patients. The results were striking: HoLEP was found to be superior to TURP in terms of efficacy, with a greater improvement in symptoms and flow rates. HoLEP was also associated with less blood loss, a shorter catheterization time, and a shorter hospital stay. This landmark study provided Level 1 evidence of the superiority of HoLEP over the long-standing gold standard of TURP.
The Elzayat et al. Long-Term Follow-up Study: Durability of HoLEP
The long-term durability of HoLEP was a key question that needed to be addressed. The study by Elzayat and colleagues, published in 2008, provided crucial long-term follow-up data on a large cohort of patients who had undergone HoLEP. The study demonstrated that the excellent outcomes of HoLEP were sustained at a mean follow-up of 7 years, with a very low reoperation rate of less than 1%. This study solidified the reputation of HoLEP as a durable and long-lasting solution for BPH.
The HORIZON Trial: HoLEP vs. Photoselective Vaporization of the Prostate (PVP)
The HORIZON trial, a multicenter randomized controlled trial, compared HoLEP to photoselective vaporization of the prostate (PVP) using the GreenLight laser. The results of this trial, published in 2012, showed that while both procedures were effective, HoLEP was superior to PVP in terms of objective outcomes, with a greater reduction in prostate volume and a more significant improvement in flow rates. The HORIZON trial provided further evidence to support the use of HoLEP as a first-line surgical treatment for BPH.
The GOLIATH Trial: HoLEP vs. TURP in Large Prostates
The GOLIATH trial was a large, multicenter, randomized controlled trial that specifically evaluated the efficacy and safety of HoLEP versus TURP in patients with large prostates (>80 mL). The results, published in 2014, confirmed the findings of previous studies, demonstrating that HoLEP was superior to TURP in this patient population. HoLEP was associated with a greater improvement in symptoms, a lower risk of complications, and a shorter hospital stay. The GOLIATH trial firmly established HoLEP as the treatment of choice for patients with large prostates.
These landmark clinical trials, along with a wealth of other supporting evidence, have unequivocally established HoLEP as a safe, effective, and durable surgical treatment for BPH. The evidence base for HoLEP is robust and continues to grow, solidifying its position as the modern gold standard for the surgical management of BPH.